Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inventiva ( (IVA) ) has shared an update.
On May 22, 2025, Inventiva held its Combined Shareholders’ General Meeting in Paris, where all resolutions were adopted except one regarding share capital increases for a company savings plan. The meeting approved the compensation policy for corporate officers, reflecting strong shareholder support for the company’s strategic directions.
The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
Inventiva’s overall stock score reflects significant financial difficulties and a challenging valuation, balanced by strong technical indicators and a cautiously optimistic outlook from the earnings call. Despite clinical progress, financial instability and operational inefficiencies present notable risks.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Average Trading Volume: 15,285
Technical Sentiment Signal: Hold
Current Market Cap: $439.5M
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.